Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/235661
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | LOXL2 promotes oncogenic progression in alveolar rhabdomyosarcoma independently of its catalytic activity |
Autor: | Almacellas-Rabaiget, Olga; Monaco, Paola; Huertas-Martinez, Juan; García-Monclús, Silvia; Chicón-Bosch, Mariona; Maqueda-Marcos, Susana; Fabra-Heredia, Isabel; Herrero-Martín, David; Rello-Varona, Santiago; Álava, Enrique de CSIC ORCID; López-Alemany, Roser; Giangrande, Paloma H.; Tirado, Óscar M. | Palabras clave: | LOXL2 Alveolar rhabdomyosarcoma Cell migration Cell invasion Metastasis Vimentin |
Fecha de publicación: | 1-abr-2020 | Editor: | Elsevier | Citación: | Cancer Letters 474: 1-14 (2020) | Resumen: | Rhabdomyosarcoma (RMS) is the most common soft tissue malignancy in childhood and adolescence. Patients with the most aggressive histological variant have an unfavorable prognosis due to a high metastasis incidence. Lysyl oxidase-like 2 (LOXL2) is a lysyl oxidase, member of a family of extracellular matrix (ECM) crosslinking enzymes that recently have emerged as important regulators of tumor progression and metastasis. We report that LOXL2 is overexpressed in RMS, suggesting a potential role for LOXL2 in RMS oncogenic progression. Consistently, transient and stable LOXL2 knockdown decreased cell migratory and invasive capabilities in two ARMS cell lines. Furthermore, introduction of LOXL2 in RMS non-expressing cells using wild type or mutated (catalytically inactive) constructs resulted in increased cell migration, cell invasion and number and incidence of spontaneous lung metastasis in vivo, independently of its catalytic activity. To further study the molecular mechanism associated with LOXL2 expression, a pull-down assay on LOXL2-transfected cells was performed and analyzed by mass spectrometry. The intermediated filament protein vimentin was validated as a LOXL2-interactor. Thus, our results suggest an oncogenic role of LOXL2 in RMS by regulating cytoskeleton dynamics and cell motility capabilities. | Versión del editor: | http://doi.org/10.1016/j.canlet.2019.12.040 | URI: | http://hdl.handle.net/10261/235661 | DOI: | 10.1016/j.canlet.2019.12.040 | Identificadores: | doi: 10.1016/j.canlet.2019.12.040 issn: 0304-3835 |
Aparece en las colecciones: | (IBIS) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
14
checked on 02-may-2024
WEB OF SCIENCETM
Citations
13
checked on 13-feb-2024
Page view(s)
62
checked on 03-may-2024
Download(s)
14
checked on 03-may-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.